Prospective cohort study of treatment outcomes of vaginal discharge syndrome in women in Windhoek, Namibia

Author:

Dunaiski Cara M.,Kock Marleen M.,Jung Hyunsul1,Peters Remco P.H.

Affiliation:

1. University of Pretoria, Department of Medical Microbiology, Pretoria, South Africa

Abstract

ABSTRACT Background Syndromic treatment is the standard of care for vaginal discharge syndrome (VDS) in resource-constrained settings. However, the outcomes of VDS treatment have not been well documented. This study aimed to determine the incidence, risk factors, and microbial etiology of treatment failure in women with VDS. Methods This prospective cohort study of women with VDS was conducted between September 2021 and March 2022 at Katutura Intermediate Hospital in Windhoek, Namibia. Microbiological analyses of sexually transmitted infections (STI) (Chlamydia trachomatis; Neisseria gonorrhoeae; Trichomonas vaginalis; Mycoplasma genitalium), bacterial vaginosis (BV), and vulvovaginal candidiasis (VVC) were performed. Treatment outcomes were assessed at 7 and 30 days after treatment, followed by microbial investigation in case of treatment failure. Results One hundred and nine women were enrolled and 94 (86%) completed the follow-up. At baseline, 37/109 (40%) women were diagnosed with STI, 47/109 (43%) with BV and 45/109 (41%) with VVC. Candida albicans (33/45; 73%) was the main pathogen in VVC, with fluconazole resistance detected in 8/33 (24%) isolates; 10/12 (80%) of non-albicans Candida species showed resistance. The incidence of treatment failure was 3.6 per 100 person-years at 7 days and 1.0 per 100 person-years at 30 days follow-up; 17/94 (18%) women had recurrent VDS and 12/94 (13%) women had persistent VDS. VVC (OR 4.3; 95% CI 1.7-11, p = 0.002) at baseline was associated with treatment failure. Conclusions Treatment failure after syndromic management of VDS is common in resource-constrained settings. Access to diagnostic testing, including fungal culture and susceptibility testing, is recommended to improve outcomes.

Publisher

Ovid Technologies (Wolters Kluwer Health)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3